| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 16 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 16, 2026, aTyr Pharma, Inc. (the “Company”) held its 2026 Special Meeting of Stockholders (the “Special Meeting”). As of September 4, 2026, the record date for the Special Meeting (the “Record Date”), 98,087,425 shares of the ... |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
Form 4: Yaras Brandon, Chief Financial Officer
Granted 410,000 Employee Stock Option (right to buy) |
| 01 Oct 2026 | Form 3: Yaras Brandon, Chief Financial Officer |
| 24 Sep 2026 |
8-K: Other Events
On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patien... |
| 11 Sep 2026 | Proxy statement: special meeting on October 16, 2026 |
| 31 Aug 2026 | PRE 14A |
| 07 Aug 2026 | S-8 |
| 07 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 07 Aug 2026 | 10-Q |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 31 Jul 2026 | 8-K: Termination of a Material Definitive Agreement |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 08 Jun 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 05 Jun 2026 | SCHEDULE 13G/A |
| 01 Jun 2026 | 8-K: Regulation FD Disclosure |
| 28 May 2026 |
Form 4: Schimmel Paul, Director
Bought 100,000 shares ($49.6K) |
| 15 May 2026 | 10-Q |
Loading...
